Cowen reissued their buy rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a research report sent to investors on Wednesday morning, AnalystRatings.com reports.

Several other equities analysts have also recently commented on the company. Morgan Stanley reduced their target price on Acceleron Pharma from $52.00 to $48.00 and set an equal weight rating for the company in a research note on Friday, October 11th. JPMorgan Chase & Co. reduced their target price on Acceleron Pharma from $61.00 to $58.00 and set an overweight rating for the company in a research note on Tuesday, August 6th. ValuEngine upgraded Acceleron Pharma from a buy rating to a strong-buy rating in a research note on Thursday, August 8th. Oppenheimer set a $58.00 price objective on Acceleron Pharma and gave the stock a buy rating in a research note on Tuesday, September 17th. Finally, Credit Suisse Group set a $58.00 price objective on Acceleron Pharma and gave the stock a buy rating in a research note on Monday, August 26th. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $57.58.

Acceleron Pharma stock opened at $43.28 on Wednesday. The stock has a market cap of $2.51 billion, a P/E ratio of -16.71 and a beta of 1.23. The company has a current ratio of 17.11, a quick ratio of 17.11 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average of $42.00 and a 200-day moving average of $42.16. Acceleron Pharma has a 52 week low of $37.01 and a 52 week high of $58.11.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.03). The business had revenue of $4.20 million for the quarter, compared to analysts’ expectations of $4.44 million. Acceleron Pharma had a negative net margin of 318.84% and a negative return on equity of 29.51%. The business’s quarterly revenue was up 27.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.63) earnings per share. As a group, equities analysts predict that Acceleron Pharma will post -2.33 earnings per share for the current fiscal year.

In other Acceleron Pharma news, SVP Ravindra Kumar sold 3,389 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $45.24, for a total value of $153,318.36. Following the sale, the senior vice president now directly owns 86,986 shares in the company, valued at $3,935,246.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Habib J. Dable sold 5,625 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $45.23, for a total value of $254,418.75. Following the completion of the sale, the chief executive officer now owns 71,227 shares in the company, valued at $3,221,597.21. The disclosure for this sale can be found here. Insiders have sold 21,422 shares of company stock worth $969,486 over the last 90 days. 2.50% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of XLRN. Tower Research Capital LLC TRC bought a new stake in Acceleron Pharma in the second quarter valued at $89,000. Convergence Investment Partners LLC bought a new stake in Acceleron Pharma in the third quarter valued at $149,000. Bank of Montreal Can lifted its stake in Acceleron Pharma by 4,163.0% in the second quarter. Bank of Montreal Can now owns 3,922 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 3,830 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Acceleron Pharma by 1,947.6% in the third quarter. Nisa Investment Advisors LLC now owns 4,300 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 4,090 shares during the last quarter. Finally, Aperio Group LLC bought a new stake in Acceleron Pharma in the second quarter valued at $190,000. Institutional investors own 90.37% of the company’s stock.

About Acceleron Pharma

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Featured Article: What are the components of an earnings report?

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.